Evidence map›Paper›PMID 27267892›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2016

STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.

Noah D Peyser, Lin Wang, Yan Zeng, Marie Acquafondata, Maria Freilino, Hua Li, Malabika Sen, William E Gooding, Masanobu Satake, Zhenghe Wang and 2 more

Abstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Noah D PeyserDepartment of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, California.
Lin WangDepartment of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Yan ZengDepartment of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, California.
Marie AcquafondataDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Maria FreilinoDepartment of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Hua LiDepartment of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, California.
Malabika SenDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
William E GoodingDepartment of Otolaryngology and the University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Masanobu SatakeDepartment of Molecular Immunology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan.
Zhenghe WangCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio. Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio.
Daniel E JohnsonDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Jennifer R GrandisDepartment of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, California. Jennifer.Grandis@ucsf.edu.
Case Western Reserve University · US

Funding

WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe · 2004 to 2026
$49.6M
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and PreventionP50CA150964 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2011 to 2022
$24.6M
STAT-Mediated TGFalpha EGFR Signaling in squamous cell carcinoma of head neckR01CA077308 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GRANDIS, JENNIFER RUBIN · 1998 to 2018
$5.0M
Mechanisms of suppression of colon cancer by receptor tyrosine phosphatase PTPRTR01CA127590 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI WANG, ZHENGHE · 2007 to 2017
$2.9M
Genomic alteration of PTPRT in OSCC: Implications for STAT3 pathway targetingF31DE024007 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PEYSER, NOAH D · 2013 to 2014
$83k
NCI NIH HHS P50 CA097190NCI NIH HHS R01 CA077308NCI NIH HHS R01 CA127590NIDCR NIH HHS F31 DE024007
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a frequently fatal disease due, in large part, to a high rate of second primary tumor (SPT) formation. The 4-nitroquinoline 1-oxide (4-NQO) mouse model of oral carcinogenesis provides a robust system in which to study chemopreventive agents in the context of chemically induced HNSCC tumors. STAT3 is a potent oncogene that is hyperactivated by tyrosine phosphorylation early in HNSCC carcinogenesis and is a rational therapeutic target. We recently reported that loss-of-function of the STAT3 phosphatase PTPRT promotes STAT3 activation in HNSCC tumors and preclinical models and may serve as a predictive biomarker of response to STAT3 inhibitors, including the small-molecule Stattic. We therefore investigated the hypothesis that Ptprt-knockout (KO) mice would be more susceptible to 4-NQO-induced oral carcinogenesis and more sensitive to Stattic-mediated chemoprevention compared with wild-type (WT) mice. Herein, we demonstrate that Ptprt WT and KO mice develop similar spectra of HNSCC disease severity upon 12 weeks of 4-NQO administration, with no apparent effect of Ptprt genotype on carcinogenesis or treatment outcome. Targeting of STAT3 with Stattic resulted in a chemopreventive effect against 4-NQO-induced oral cancer (P = 0.0402). While these results do not support a central role for PTPRT in 4-NQO-induced HNSCC carcinogenesis, further investigation of STAT3 as a chemoprevention target in this cancer is warranted. Cancer Prev Res; 9(8); 657-63. ©2016 AACR.

Indexed as

4-Nitroquinoline-1-oxideAnimalsBiomarkersCarcinogensCarcinoma, Squamous CellChemopreventionCyclic S-OxidesHead and Neck NeoplasmsMiceMice, KnockoutMouth NeoplasmsReceptor-Like Protein Tyrosine Phosphatases, Class 2Squamous Cell Carcinoma of Head and NeckSTAT3 Transcription FactorTime Factors4-Nitroquinoline-1-oxideBiomarkersCarcinogensCyclic S-OxidesPtprt protein, mouseReceptor-Like Protein Tyrosine Phosphatases, Class 2STAT3 Transcription Factorstattic

Identifiers

PMID27267892
PMCPMC4970880
OpenAlexW2412431495

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.